Hematology · Pediatrics · Oncology · 3 h ago
ALBI Score Associated With Hospital Mortality After VOD in Pediatric Transplant Cohort
A single-center retrospective study of 43 patients aged 0–26 years with veno-occlusive disease after hematopoietic stem cell transplantation found that day-7 albumin–bilirubin scores were associated with hospital mortality. Scores improved in survivors but worsened in non-survivors during the week after diagnosis.
- Cohort included 43 transplant recipients with VOD; seven died.
- Day-7 ALBI scores were associated with hospital mortality.
- Preconditioning scores did not distinguish survivors from non-survivors.
- Small retrospective cohort limits clinical application.
A single-center retrospective study in Pediatric Blood & Cancer evaluated the albumin–bilirubin (ALBI) score as a prognostic marker in patients aged 0–26 years who developed veno-occlusive disease (VOD) after hematopoietic stem cell transplantation during 2019–2024. Investigators calculated scores at prespecified time points from preconditioning through the period after VOD diagnosis. The primary outcome was hospital mortality.
Among 43 patients with VOD, 33 (77%) underwent transplantation for cancer and seven (16%) died. Median ALBI scores increased from −3.00 before conditioning to −1.70 at VOD diagnosis (p < 0.001), indicating worsening liver function. Preconditioning scores did not differ between survivors and non-survivors. During the week after diagnosis, scores improved in survivors but worsened in non-survivors.
At seven days after diagnosis, ALBI scores were higher in non-survivors (p = 0.008), with an area under the receiver operating characteristic curve of 0.83. Severe ALBI classification using an established cutoff was associated with greater odds of hospital mortality (OR 8.3; 95% CI 1.4–48.5). A difference three days before diagnosis was not statistically significant.
ALBI may offer an accessible adjunct to VOD prognostication, but the small, single-center retrospective cohort and wide confidence interval limit certainty. The findings establish an association rather than a validated basis for treatment decisions; this report is based on the abstract only.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Pediatric Blood & Cancer: Albumin–Bilirubin Score Is Associated With Veno‐Occlusive Disease‐Related Mortality in Children Post‐Hematopoietic Stem Cell Transplant ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.